TriSalus Life Sciences, Inc. Other Current Liabilities
TriSalus Life Sciences, Inc. (TLSI) had Other Current Liabilities of $58.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Liabilities, Current $58.00K.
- 2026-03-31: Other Liabilities, Current $269.00K.
- 2025-12-31: Other Liabilities, Current $234.00K.
- 2025-09-30: Other Liabilities, Current $224.00K.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $58.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $269.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $234.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $224.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $221.00K 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $426.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $383.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $329.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $291.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $260.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $389.00K 10-K/A · filed 2025-05-30 | |
| 2023-09-30 | $427.00K 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $142.00K 10-K · filed 2024-04-11 | $48.13K 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |